Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Up to two hundred (200) adult participants with type 1 diabetes (T1D) aged 18 to 75 years
will be selected for inclusion in the study. The target is to obtain treatment response and
user-experience data following use of nasal glucagon (AMG504-1) in treating episodes of
hypoglycemia. The population will be enriched to include participants who suffer from
impaired hypoglycemia awareness.